---
title: "Xenetic Biosciences, Inc. (XBIO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/XBIO.US.md"
symbol: "XBIO.US"
name: "Xenetic Biosciences, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T23:18:34.083Z"
locales:
  - [en](https://longbridge.com/en/quote/XBIO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/XBIO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/XBIO.US.md)
---

# Xenetic Biosciences, Inc. (XBIO.US)

## Company Overview

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company’s product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.xeneticbio.com](https://www.xeneticbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:19.000Z

**Overall: B (0.37)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 58 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 23.52% |  |
| Net Profit YoY | 39.10% |  |
| P/B Ratio | 0.93 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6495143.76 |  |
| Revenue | 3190073.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -37.02% | E |
| Profit Margin | -70.03% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 23.52% | A |
| Net Profit YoY | 39.10% | B |
| Total Assets YoY | 36.57% | A |
| Net Assets YoY | 35.67% | A |
| Cash Flow Margin | 81.52% | C |
| OCF YoY | 23.52% | A |
| Turnover | 0.47 | C |
| Gearing Ratio | 12.12% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Xenetic Biosciences, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "23.52%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "39.10%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.93",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6495143.76",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3190073.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "-37.02%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-70.03%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "23.52%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "39.10%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "36.57%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "35.67%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "81.52%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "23.52%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.47",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "12.12%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.91 | 291/385 | - | - | - |
| PB | 0.93 | 87/385 | 1.40 | 1.12 | 0.96 |
| PS (TTM) | 2.04 | 51/385 | 2.36 | 2.02 | 1.80 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2025-10-30T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.94 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/XBIO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/XBIO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/XBIO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/XBIO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**